Our convertibleCAR™ and MicAbody™ proteins technology platform represents an exciting new approach to the precise control and targeting of CAR-T and –NK cell to fight cancer. Xyphos is currently evaluating partnership opportunities for research and development programs exploring applications of our technologies.

To partner with us contact:

Chuck Vacin
Business Development
Office: (650) 243-2951
Fax: (650) 362-6585
Email: chuck@avidbiotics.com